You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

LEXAPRO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lexapro, and what generic alternatives are available?

Lexapro is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in LEXAPRO is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lexapro

A generic version of LEXAPRO was approved as escitalopram oxalate by AMNEAL PHARMS on March 14th, 2012.

  Try a Trial

Drug patent expirations by year for LEXAPRO
Drug Prices for LEXAPRO

See drug prices for LEXAPRO

Drug Sales Revenue Trends for LEXAPRO

See drug sales revenues for LEXAPRO

Recent Clinical Trials for LEXAPRO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2/Phase 3
National Center for Complementary and Integrative Health (NCCIH)Phase 2/Phase 3
University of MichiganPhase 2/Phase 3

See all LEXAPRO clinical trials

Pharmacology for LEXAPRO
Paragraph IV (Patent) Challenges for LEXAPRO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXAPRO Capsules escitalopram oxalate 5 mg 021323 1 2005-08-17
LEXAPRO Capsules escitalopram oxalate 10 mg and 20 mg 021323 1 2005-03-30

US Patents and Regulatory Information for LEXAPRO

LEXAPRO is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting LEXAPRO

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie LEXAPRO escitalopram oxalate SOLUTION;ORAL 021365-001 Nov 27, 2002 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LEXAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie LEXAPRO escitalopram oxalate SOLUTION;ORAL 021365-001 Nov 27, 2002 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LEXAPRO

See the table below for patents covering LEXAPRO around the world.

Country Patent Number Title Estimated Expiration
Morocco 27349 ⤷  Try a Trial
Hong Kong 139596 New enantiomers and their isolation ⤷  Try a Trial
Croatia PK20080410 SMJESA U KRISTALNOM OBLIKU KOJA SADRŽI ESCITALOPRAM (CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM) ⤷  Try a Trial
Finland 941829 ⤷  Try a Trial
South Korea 20040028947 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LEXAPRO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0347066 2002C/039 Belgium ⤷  Try a Trial PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
0347066 SPC/GB02/049 United Kingdom ⤷  Try a Trial PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610
0347066 10399030 Germany ⤷  Try a Trial PRODUCT NAME: ESCITALOPRAMOXALAT; NAT. REGISTRATION NO/DATE: 55880.00.00 55880.01.00 55880.02.00 55880.03.00 55884.00.00 55884.01.00 55884.02.00 55884.03.00 55888.00.00 55888.01.00 55888.02.00 55888.03.00 20030408 FIRST REGISTRATION: SCHWEDEN 17084 17085 17086 17087 20011207
0347066 C300155 Netherlands ⤷  Try a Trial PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427
0347066 42/2002 Austria ⤷  Try a Trial PRODUCT NAME: ESCITALOPRAM UND DESSEN NICHT-TOXISCHE SAEUREADDITIONSSALZE; NAT. REGISTRATION NO/DATE: 1-24549, 1-24550, 1-24551, 1-24552 20020618; FIRST REGISTRATION: SE 17084, 17085, 17086,17087 20011207
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.